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Most T cells express the antigen-specific MHC-restricted TCR-ce//3, whereas the
TCR--y/b is expressed on small subpopulations ofPBL and thymocytes (1, 2) . Cell-
mediated lysis of certain tumor targets without restriction by theMHC can be ac-
complished by NK cells (3-5) and y/6 T cells (6-9) . Despite intensive studies, the
mechanism of non-MHC-restricted E/T cell recognition remains unclear (10, 11) .
In general, distinct patterns ofnon-MHC-restricted cytolysis have notbeen associated
with particular clones of effector cells and their surface structures .
To study the specificity and function of T cells bearing theTCRy/b (11-14), we
compared the non-MHC-restricted cytotoxic activity of y/b andNK cell clones . We
examined NK clones and y/bT cell clones derived from the same healthy individ-
uals for target selectivity, and found that the y/b clones mediated a pattern of cyto-
toxicity on tumor cell lines that was markedly different from that mediated byNK
cell clones . The cytotoxic activity of the y/b T cell clones was influenced by mAbs
directed against the CD3/TCR-y/b complex . Our findings indicate that the TCR-
y/b may be involved in the distinct pattern of non-MHC-restricted cytolysis medi-
ated by y/b T cell clones on certain tumor target cells such as the Daudi cell line,
possibly at the level of E/T cell recognition .
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Materials and Methods
Cytotoxic Clones .
￿
PBMC were isolated by Ficoll-Hypaque sedimentation of heparinized
blood samples ; most experiments described involve PBL obtained from one healthy volun-
teer blood donor. These were positively selected by FAGS for cells expressing the Leu-19 an-
tigen (predominantly NK cells), theCD16 (Leu-11a) antigen (NK cells), or y/bT cells . The
sorted cellswere cloned by limiting dilution at 0.3 cellsper well (5, 6, 15) . The culturemedium
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was RPMI 1640, supplemented with 2 MM L-glutamine, 100 IU/ml penicillin, 100 Ag/ml
streptomycin (all from Whittaker M. A. Bioproducts, Walkersville, MD), 25 mM Hepes buffer
(Sigma Chemical Co., St. Louis, MO), and 10% heat inactivated human serum (Pel-Freeze
Biologicals, Rogers, AR). The plated cells were stimulated with 500 U/ml rIL-2 (Hoffmann-
La Roche, Nutley, NJ) and a mixture of irradiated allogeneic or autologous feeder cells (2 x
104 PBL and 104 EBVtransformed lymphoblastoid B cell lines [LCL]) as described (5, 6).
The clones were expanded by replating at weekly intervals with feeder cells, fresh medium,
IL-2, and PHA (0.25 ug/ml; Wellcome Diagnostics, Beckenham, UK).
mAbs andImmunofluorescence.
￿
For immunofluorescence studies, cells were labeled with mAbs
reactive against CD2 (Leu-5b), CD3 (Leu-4), CD4 (Leu-3a), CD8 (Leu-2b), CD16 (Leu-
11a), CD56 (Leu-19) epitopes, and TCRa/(3 (WT31) (all from Becton Dickinson & Co., Moun-
tain View, CA) . mAbs reactive with all cells expressing the TCRy/b were TCR61 (T Cell
Sciences, Cambridge, MA) and TCRy/b-1 (8, 16). In addition, some y/6 clones were stained
with mAbs that detect specific V region determinants on the TCRy/b. These mAbs were
Ti-yA (a gift from F. Triebel and T. Hercend [171), BB3 (a gift from L. Moretta [18]), and
6 TCSI (provided by T Cell Sciences [161). mAbs against LFA-Ice (TSl/22), LFA-1(3 (TSl/18),
ICAM-1 (RRl/1), and LFA-3 (TS2/9) were donated by T. Springer (Center for Blood Re-
search, Boston, MA). For direct fluorescence, cells were labeled with mAbs conjugated to
FITC or phycoerythrin (PE) in PBS (30 min at 4°C) and washed. For indirect fluorescence,
cells were exposed to mAbs, subsequently incubated with FITC-conjugated goat anti-mouse
antibody (Becton Dickinson & Co.), and washed before analysis by FACS. In each experi-
ment, nonspecific binding was subtracted using appropriate isotype controls. The mAbs in-
cluded in cytotoxicity assays were TCRy/&1; mAb reactive to the T112 and T113 epitopes
ofthe CD2 molecule (a gift from S. Schlossman, Dana-Farber Cancer Institute, Boston, MA),
mAb reactive to CD3 (UCHTI, kindly provided by I? Beverley, University College Hospital,
London, UK), and mAb directed against HLA-DR (1,234), -DQ(S3/4), and -DP (B7/21.2),
(donated by F. Bach, University of Minnesota, Minneapolis, MN).
Cell-mediated Lysis (CML) Assay.
￿
The clones were washed and assayed for cytotoxicity by
incubation in 96-well round-bottomed microtiter plates (Costar, Cambridge, MA) with 5 x
103 "Cr-labeled target cells for 4 or 6 h at 37°C as described (19). Percent specific lysis was
calculated as 100 x [(counts per minute released with effectors - counts per minute released
alone)/(counts per minute released by detergent) - (counts per minute released alone)] . Cy-
totoxicity values obtained from serial E/T ratios were converted into LU. One LU was defined
as the number of effector cells required to achieve 20% specific lysis of5 x 103 targets. Tumor
target cell lines (19) K562, Molt 4, U937, and Raji were obtained through the American
Type Culture Collection (Rockville, MD). The Daudi cell line and the variant 02m-Daudi
(transfected with the mouse R2-microglobulin gene and thus expressing MHC class I anti-
gens) were a gift from J. Parries (Stanford, CA). The LCL TK6 is a derivative of WI-1,2,
obtained from W. Thilly (M. I. T., Cambridge, MA). These cell lines were maintained in
RPMI containing 10% FCS (HyClone Laboratories, Logan, UT). Mycoplasmacontamina-
tion was excluded.
Results and Discussion
Initially, we examined distinct tumor target cell lines (15, 19) for cytolysis by these
clones (Table 1). Clones selected by FACS for TCRy/b expression from a culture
primed to the LCL TK6 mediated a very high level of cytotoxicity on Daudi cells
but failed to lyse the Raji cell line (Table I). In marked contrast, NK clones obtained
from PBL of the same donor lysed the Daudi and Raji targets equally well (Table
II). Disparate lysis of these two target lines by y/S clones and NK clones was remark-
able since both Daudi and Raji are quite similar cells derived from Burkitt's lym-
phomas. The Daudi cell line is deficient for HLA class I antigens due to defective
(32m synthesis but expresses HLA class II antigens, while Raji expresses both HLA
class I and II. Although- non-MHC-restricted lysis appears to correlate inversely
with the expression of HLA class I antigens on some target cells (20, 21), this doesFISCH ET AL.
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TABLE I
Clones Obtained by Sortingfor TCR-y/8-1+ Cellsfrom Primed Culture
The clones were derived from a culture of PBL primed to the LCL TK6 for 7 d followed by FACS sorting
for TCR-y/b' cells. Clones were screened for cytotoxicity on the indicated target cell lines. The results in-
dicating percent cytotoxicity were obtained in experiments where equal volumes (25 pl) ofmedium in wells
containing the clones were transferred to plates to which the target cells were subsequently added. Two or
three replicates were performed per clone; SD for percent cytotoxicity was usually <3% . Autologous y/b
clones and NK clones were simultaneously compared. The experiments in Tables I, II, IV, and VI represent 2
of 24 similar experiments. The phenotypes of the clones in Table I were determined by direct immunofluores-
cence. Values shown for binding of mAbs are expressed as percent positive cells, and data are rounded to
the decimal point. Clone type designations for Tables I-V are defined as NK for CD3- cells that are CD16'
and/or CD56' ; y/b for CD3' cells that were found to be TCR-'Y/6-1 or TCR-61' and WT31 - ; and a/S
for CD3' cells that are TCR-,y/6-1 - and WT31' . The results shown reflect typical response patterns selected
from 284 clones evaluated for Table I.
not provide an explanation for the particular pattern of cytotoxicity by these 'r/6
clones. First, virtually all NK clones lysed Raji as well as or even better than Daudi
targets and, second, an HLA class I-expressing Daudi variant was strongly killed
byall they/b clones (Table III). Ally/b clones and NKclones mediated non-MHC-
restricted cytolysis against HLA antigen-deficient K562 target cells. Both NK and
TABLE II
Clones Obtained by Sortingfor CD16' Cellsfrom PBL
The clones were derived from fresh PBL sorted for CD16 (Leu-11)' cells. LCL used as stimu-
lators were TK6 . Clones were screened for cytotoxicity on the indicated target cell lines. The
results indicating percent cytotoxicity were obtained in experiments where equal volumes (25
pl) ofmedium in wells containing the clones were transferred to plates to which the target cells
were subsequently added. Two or three replicates were performed perclone; SD for cytotoxic-
ity was usually <3% . Autologous y/b clones and NK clones were simultaneously compared.
The phenotypes ofthe clones in Table II weredetermined by direct immunofluorescence. Values
shown for binding of mAbs are expressed as percent positive cells, and data are rounded to
the decimal point. Clone type designations are defined as in Table I. The results shown reflect
typical response patterns selected from 90 clones evaluated for Table II.
Percent specific binding of mAb Percent cytotoxicity
Clone Type CD3 TCR-61 CD16 CD56 CD4 CD8 K562 Daudi Raji TK6
GPC4 y/5 99 100 0 39 0 95 42 53 2 12
GPE5 y/b 99 99 0 30 0 1 27 66 0 25
GAK4 y/3 99 99 0 30 0 43 41 58 3 35
GAC 1 y/b 100 99 9 63 0 1 15 59 4 18
GAH1 -Y/b 99 99 2 3 ND ND 38 56 0 25
GAH2 y/b 100 99 0 63 0 15 58 78 6 22
GAF2 y/b 100 100 ND 56 0 86 34 61 5 12
GAG1 y/b 99 97 ND 79 0 55 58 78 5 22
GAG2 'r/b 99 99 ND 76 0 1 42 57 2 13
GAB1 NK 0 0 0 99 0 0 85 79 100 89
Clone Type
Percent specific
CD3 TCR61
binding
CD16
of mAb
CD56 K562
Percent
Daudi
cytotoxicity
Raji TK6
NAD1 NK 2 0 94 99 82 54 47 52
NAA1 NK 1 0 91 97 83 81 86 23
NAM NK 1 ND 93 99 73 75 85 59
NAC2 NK 3 ND 99 99 61 11 53 31
NEE6 NK 2 ND 98 96 86 41 46 25
NEEI NK 1 ND 99 99 90 55 60 541570
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TABLE III
Target Selectivity of Representative Clones
Percent cytotoxicity mediated by 10 representative clones is shown at three E/T ratios when
tested for lysis against the six target cell lines indicated. The clone type designations are listed
as in Table 1. LCL indicates the particular stimulator LCL for each of these clones .
.y/S T cell clones also lysed the cell lines TK6, Molt4 (Tables I-V), and U937 (not
shown). However, in contrast to NK clones, lysis of these target cells was weaker
than thecytotoxicity againstDaudi cellsiflower E/Tratios were compared (Table III).
This characteristic cytotoxic pattern was independentofpriming to theLCL TK6
invitro before FACS selection. Clones obtained aftersorting offresh PBL forTCR
y/6-1+ cells and stimulation with different feeder LCL (including the autologous
LCL) had an identical pattern of cytotoxicity (Table IV). All 356 -Y/6 clones that
wereobtained fromthis donor'sfresh PBLwithout "priming"to TK6 mediated high
levels oflysisonDaudi cells butvirtuallynokillingon theRajicellline. These clones
Clone LCL Type E/T K562
Percent
Daudi
cytotoxicity
02rn
Daudi
on target
Molt 4
cell line
Raji TK6
RAD6 TK6 NK 9 80 81 71 86 82 68
3 72 62 56 77 78 57
1 58 31 28 58 41 40
GABI TK6 NK 3 70 70 65 57 81 68
1 75 57 52 41 67 57
0.3 64 28 20 25 43 41
BC5 TK6 NK 9 73 60 68 60 81 35
3 49 33 38 47 54 17
1 26 19 15 24 32 7
GPC4 TK6 y/6 6 44 79 69 50 1 28
2 32 85 63 47 1 23
0.7 25 83 57 28 2 16
GAC1 TK6 y/6 9 14 70 63 27 6 11
3 6 63 61 18 4 9
1 2 42 40 9 2 7
F135 PF y/6 9 53 77 74 70 6 42
3 43 74 62 58 3 33
1 23 72 65 41 1 31
MI-13 RM y/6 9 11 61 ND 40 3 42
3 9 52 ND 40 3 35
1 3 49 ND 35 1 29
P14 PS ti/6 9 62 81 71 86 9 34
3 31 72 63 63 7 13
1 16 73 59 50 1 5
API TK6 a/(3 9 51 5 8 29 9 41
3 28 2 2 5 5 17
1 14 1 0 1 1 5
AW4 PF 01/0 9 46 0 1 56 4 45
3 22 2 1 43 2 23
1 7 9 9 25 1 5FISCH ET AL.
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TABLE IV
Clones Obtained by Sortingfor TCR-y/8-1+ Cellsfrom PBL
The clones were derived from fresh PBL sorted for TCR-'y/b-1+ cells. LCL used as stimulator cells were
PF-, PS-, and RM-LCL for clones with initials F, P, and M, respectively. Clones were screened for cytotox-
icity on the indicated target cell lines including the specific stimulator LCL. The results indicate percent cytotox-
icity were obtained in experiments where equal volumes (25 Wl) of medium in wells containing the clones
were transferred to plates to which the target cells were subsequently added. Two or three replicates were
performed per clone; SD for percent cytotoxicity was usually <3% . Autologous y/b clones and NK clones
were simultaneously compared. The phenotypes of the clones in Table IV were determined by indirect im-
munofluorescence. Values shown for binding ofmAbs are expressed as percent positive cells, and data are
rounded to the decimal point. Clone type designations are defined as in Table I. The results shown reflect
typical response patterns selected from 211 clones evaluated for Table IV.
also killed K562, and many but not all clones also effectively destroyed TK6. How-
ever, these y/bclones did not lyse the particularLCL used to stimulate them, except
for TK6. These stimulator LCL were susceptible to cytolysis by NK clones and al-
loreactive a/a T cell clones. The exclusive pattern ofcytotoxicity by these y/b T cell
clones was reproducedin >40experiments with some ofthese clones. Moreover, anal-
ogous results were obtained when these same y/b clones (seven of seven) were tested
in Rotterdam on TK6 cells and on independently maintained K562, Daudi, Raji,
and LCLtargets. In contrast tothese y/b clones, all TCRa/(3clones with non-MHC-
restricted cytotoxic activity against K562 that were obtained from the same donor
(33 clones)did notlyse Daudior Raji cells, althoughmanyclones lysed Molt4 and/or
TK6 targets (representative clones shown in Tables III and IV).
Phenotypic analysis with mAbs (Tables I, II, IV, and V Figure 1) identified the
NK clones as Leu-11a (CD16)' or Leu-11a- and Leu-19 (CD56)+, but TCR61 -while
they/b clones were TCRy/b-1+, TCRb1 + (mAbs reactive with ally/b cells [8, 16]).
Most y/b T cell clones were double negative for CD4 and CD8, but some clones
expressedvariablelevels ofCD8. Particularlystrikingwere rare clones that markedly
lysed Raji, obtained from cells that had been sorted for TCR'y/b-1 +. All of these
were subsequently proven to be NK clones rather thany/bT cell clones (presumably
contaminants in the sorted cells, i.e., clone GAB1; Table I, Fig. 1). Furthermore,
some clones that were derived from a sort for Leu-19+ PBL mediated the pattern
of lysis corresponding to that ofthe ti/bclones (Table V). Indeed, all such clones
were shown to be Leu-19' y/b T cell clones and not NK clones; clones that displayed
Percent specific binding of mAb Percent cytotoxicity
Clone Type CD3 WT31 TCR-,y/6-1 CD4 CD8 K562 Daudi Raji TK6 LCL
FB5 y/b 100 3 100 8 6 66 86 29 56 0
FK4 'Y/b 100 2 100 1 2 61 67 8 47 3
MB5 'Y/b 100 0 100 2 1 50 68 11 21 4
MB6 'Y/b 100 2 99 0 1 73 61 4 18 4
MC 1 y/b 99 2 99 3 5 55 60 7 12 3
ME1 'Y/b 99 ND 99 0 90 69 74 12 30 0
MH3 'Y/b 98 5 100 ND ND 39 80 4 40 1
MK4 -Y/b 100 ND 100 0 24 70 70 9 23 10
PCI 'r/b 100 3 100 1 2 72 80 9 0 0
PD4 'Y/b 99 1 100 1 1 65 71 6 23 6
P14 -Y/b 99 5 100 1 4 64 72 6 22 0
PJ2 'Y/b 100 1 99 0 1 49 67 2 6 01572
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TABLE V
Clones Obtained by Sortingfor CD56' Cellsfrom PBL
The clones were derived from fresh PBL sorted for Leu-19 (CD56)' cells. LCL used as stimulator cells were
TK6. Clones were screened for cytotoxicity on the indicated target cell lines. The results indicating percent
cytotoxicity were obtained in experiments where equal volumes (25 Al) of medium in wells containing the
clones were transferred to plates to which the target cells were subsequently added. Two or three replicates
were performed per clone; SD for percent cytotoxicity was usually <3% . Autologous .y/S clones and NK-
clones were simultaneously compared in each experiment. The phenotypes of the clones in Table V were
determined by indirect immunofluorescence. Values shown for binding of mAbs are expressed as percent
positive cells, and data are rounded to the decimal point. Clone type designations are defined as in Table I .
The results shown reflect typical response patterns selected from 338 clones evaluated for Table V .
a different pattern ofcytotoxicity were proven to be NK clones or, rarely, TCR a/(3
clones. 20 representative y/S clones were phenotyped with additional mAbs that react
with specific V region-encoded protein products and thus detect functional TCR
gene rearrangements. As described for the majority of peripheral blood y/S cells
(16), all 20 clones were TiyA+ (reactive withVy9 [17]) and BB3+ (reactive withV62
[18]). However, all these clones lacked the determinant recognized-by mAb STCS1
(reactive with VS1[16]). The phenotype ofthese clones is consistent with the FRCS
analysis ofthis donor's peripheral blood y/S cells that seem BB3+ and TiyA+, but
are STCS1-.
Sincethe expression oftheTCRy/Scorrelatedwiththe particular pattern ofcyto-
toxicityonthesetumorcell lines, we investigated the role oftheCD3/TCRy/Scom-
plex in target cell lysis (Figs. 2 and 3). The effect of anti-CD3 mAb depended on
FcR expression on target cells (5, 9, 22). Theantibody was inhibitorywhen included
in the cytotoxicity assay with FcR- targets such as Molt 4 and TK6 (not shown),
while the lysis ofthe FcR+ Daudi and Raji cells (Fig. 2) was enhanced due to cross-
linking of the effector and target cells via FcR (9, 22). Induction of Raji cells lysis
Percent specific binding of mAb Percent cytotoxicity
Clone Type CD3 WT31 TCR-fS-1 CD16 CD56 K562 Daudi Raji TK6
RAD6 NK 0 0 0 99 99 70 64 88 57
CE1 NK 0 0 0 100 100 79 9 7 1
BD2 NK 2 2 2 97 100 80 69 80 61
BC5 NK 2 1 2 90 95 30 43 50 14
AD1 NK 3 3 4 90 99 43 18 30 0
BC7 NK 2 ND ND 90 99 74 81 84 88
AF1 NK 1 0 1 87 98 84 84 84 91
BG5 NK 2 ND 1 70 99 87 91 82 18
BE4 NK 2 ND ND 66 100 79 77 67 92
BD6 NK 4 ND ND 29 97 77 83 79 64
BB10 NK 1 0 0 18 84 54 37 40 85
BG14 a/0 100 100 1 8 59 40 1 1 60
AG2 a//3 99 100 0 2 0 0 0 1 1
API a/0 100 100 5 1 0 47 0 1 32
BB6 7/S 92 3 88 6 62 76 78 17 10
BB1 y/S 98 9 95 25 59 37 35 4 1
CC5 y/S 100 3 97 3 9 68 82 6 45
BG3 ti/S 98 5 98 7 100 45 56 7 6
BC3 'Y/S 99 12 98 9 53 76 78 16 92
AM4 .y/S 99 3 98 1 49 63 75 8 51D
U
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by anti-CD3 mAb indicates that the very inefficient lysis of Raji cells by effector
y/6 T lymphocytes in the absence of anti-CD3 was due to nonrecognition rather
than intrinsic resistance of Raji cells to the lytic machinery of these clones. Appro-
priate concentrations of the TCRy/6-1 mAb (which is of the same isotype as the
anti-CD3 mAb) were inhibitory for they/6 T cell-mediated lysis of Daudi, Molt 4,
and, although less, forTK6 target cells(Figs. 2 and3). On the contrary and in agree-
ment with published data (9, 23), the lysis of FcR' K562 and U937 target cells was
augmented in the presence of TCR-y/6-1 mAb. Nevertheless, in some experiments,
higher concentrations of the TCR-y/6-1 mAb had a mild inhibitory effect on the
lysis of K562 (as shown in Fig. 3) and U937 cells(not shown). This effect may result
from a competition between stimulatory and inhibitory signals depending on the
mAb, its concentration, and the mechanism of E/T cell interaction. The stimula-
tory signals may include in this system FcR mediated crosslinking (9, 22) and the
augmentation of E/T adhesion through LFA-1 after CD3 crosslinking (24). The in-
hibitory signals may be a consequence of the interference of the mAb with specific
recognition structures on the effector cell and/or an intracellular negative signal
affectingtheefficacy ofTcell stimulation (8, 25). As the concentration of the TCR
y/6-1 antibody increased, the inhibitory effects outweighed the inducing capacity
on FCR+ targets and, thus, the overall results shifted towards inhibition. In contrast
to some reported findings (26, 27) showing that only very low mAb concentrations
were blocking thecytotoxic activity by y/ST cells against allogeneic lymphoblastoid
cell lines (favoring the idea of transmission of a negative signal), we detected max-
imal inhibition at high concentrations. This is compatible with the view that the
mAb interfered with the TCRmediatedrecognition and/or delivered negative signals.
Incubation of the clones for 18 hin culture medium containing either the anti-CD3
or TCRy/6-1 mAb caused a marked decrease of TCR density on these 'Y/6 cells
(not shown). Preincubation oftheclones with the anti-CD3 mAb (followedby washing)
augmented lysis of the Daudi and Raji cells but inhibited lysis of Molt 4, and their
pretreatment with the TCRy/S-1 mAb abrogated the cytolysis on both Daudi and
IgGI IgG1 IgGI IgGI
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Specific effect of anti-CD3 and TCR,y/5-1 mAbs on cytolysis by BB3/Ti-yA' "y/S T
cell clones. Representative ,y/6 T cell clone GPC4 (TCR--y/6l', CD3') and NK clone RAD6
(TCR-y/&-1-, CD3-, CD16', Leu-19') were tested (4-h "Cr releaseassay) for the lysis ofDaudi
and Raji cells (E/T ratio of 3:1 shown). Cytotoxicity was measured in medium (med) and in
medium containing the indicated dilution (vol/vol; indicated on the abscissa) of mouse ascites
with anti-CD3 mAb(UCHTI, IgGl)or purified TCR-y/6-1 mAb(IgGI). Both mAbs were present
throughout the assay. Other,y/6 clones were also studied (GPE5, MB5, MH3, FB5, and PI4)
and showed similar results.
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Molt4 targets (Fig. 4). Although most of the TCR had been downmodulated by
TCRy/S-1 oranti-CD3 pretreatment, a further exposure to anti-CD2 or anti-CD3
mAb, added in the beginning ofthe cytotoxicity assay, still resulted in strong lysis
ofboth Raji and Daudi targets(Fig. 4). Thus, the blocking ofcytotoxicity by TCR-
-y/S-1 mAb wascaused byneitherasimple inhibition ofthe effectors'lyticmachinery
nortoxicity to thecell. The cytotoxic activity againstDaudi cells, but not Raji cells,
was displayed by all BB3/TiyA' y/S clones. This lytic pattern contrasts with the dis-
tinct target cell susceptibility found in NK clones and a//3 T cell clones. Moreover,
lysis ofsometarget cells can be blocked byTCRy/&-1 mAb while the lytic machinery
ofthese cells appears intact. These results suggest that the CD3/TCRy/S complex
on our y/6 T cell clones could be involved in the recognition of determinants on
certain targets such as Daudi cells. The lysis of K562 and U937 cells by our 'Y/S
clones was not effectively blocked in the presence of antiTCR mAb. It is difficult
todetermine ifthis apparent lack ofantiTCR blockingoflysisresultedfromadeficit
ofinhibitory signals or a predominance ofstimulatory signals. Relevant to this may
be the observation that the capacity ofall y/S and a//3 clones to kill K562 and U937
disappeared when the clones were passaged in vitro for many weeks (although our
y/S clones maintained the ability to lyse Daudi cells). These findings may suggest
that the cytotoxic activity by our y/S clones against K562 and U937 cells was medi-
GPC4 : Daudi GPC4 Raji
\0~0
\0
~
0 ~0-0
~0
RAD6 : Daudi RAD6 : Roji
"\°~ 0
0-0 Anti-y6
"-" Anti-CO360
50
40
30
20
10
0
0
U 90
80
70
60
50
40
30
20
10
0
0 Daudi
p MoU
0 TO
" U937
" K562
Raii
0 0.01 0.03 0.1 0.3 1 3 9
lug mAb TCRy6-1
FISCH ET AL.
￿
1575
FtoURE 3.
￿
Influence ofTCRy/81
mAb on lysis by BB3/Ti-yA' ,y/bT
cell clones on different target cells.
Theeffects ofTCR-,y/bl mAbwere
studied on target cells for BB3/
TiyA' clones (performed as the
experiment shown in Fig. 2). Rep-
resentative clone GPC4 (E/T ratio
10:1) was incubated with serial di-
lutions of the mAb and tested for
lysison thetarget cells indicatedin
a, 5-hcytotoxicity assay. Theresults
for this clone in one such experi-
ment are shownforDaudi, Molt 4,
and TK6 in the upper panel and
forU937, K562, and Raji cells in
thelower panel. Five other clones
were studied with qualitatively
similar results, although in some
experiments, somewhat greater in-
hibition on lysis of TK6 was ob-
served.
ateddifferentlythan that againstDaudi. Our datacorroborate recent results reporting
a similar specificity ofpolyclonal BB3/TiyA+, STCS1- T cell lines (23) and the in-
hibitory effects of antiTCR mAb on the lysis of K562, U937 (9, 23), and Daudi
cells (23), as well as Molt 4 cells (9, 28). Other investigators (27) have reported that
the lysis of Molt 4 cells by allospecific STCS1+ -y/S T cell clones is augmented in
the presence ofanti-CD3 or STCSI mAb, and only Leu-19' displayed non-MHC-
restricted activity. Theirresults are not necessarily in contrast to ourdata since our
clones are clearly different: our clones are all 6TCSI- and mediate non-MHC-
restricted cytotoxicity regardless of Leu-19 expression.
An alternative explanation for blocking ofcytotoxicity by antiTCR mAb could
be negative signaling elicited by certain types of TCR occupancy. Since the TCR
y/S may not be directly involved in the y/S T cell/target cell interaction, there is
a possibility that the cell surface molecules mediating effector target cell adhesion
(29), such as LFA-1, ICAM-1, CD2, and LFA-3, are the essential recognition struc-
tures. However, we have found these receptors equally expressed on all y/S T cell
clones, NK-, and a/j3 T cell clones examined, and we identified no ligand on Daudi
(LFA-1 -, ICAM-1+, CD2-, LFA-3-) that was'not present on Raji (LFA-1+, ICAM-
1+, CD2-, LFA-3+) (not shown). Therefore, it seems quite unlikely that the differen-
tial expression of these molecules could account for the particular pattern ofcytol-
ysis displayed by our y/S T cell clones. Nevertheless, other yet unknown structures
distinct from theTCR and these adhesion molecules could be functional in thelytic
mechanism used by y/S T cells.1576
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Triggering oflysisthrough
CD3 andCD2epitopes aftermodula-
tionoftheTCRy/&Clone GPC4 was
incubatedfor18 hin medium, or with
either anti-CD3 mAb(UCHT1, 1:200)
or TCRy/6-1 (1:100). This resulted in
marked, although notcomplete,modu-
lation oftheTCRy/6andCD3 mole-
cules(not shown).Afterwashing(three
times), cells were tested for lysis of
Daudi, Raji (bothFCR'), and Molt 4
(FcR-) (E/T ratios of 5, 1, and 0.2 to
1; 6-hCMLassay).Data areexpressed
as LU per 106 effectors. Anti-CD3
mAb(UCHTI at 1:200, vol/vol),or a
mixture of antiT112 plus antiT113
mAb (1 :800, vol/vol) were added to
some ofthewells. Asimilarpatternwas
seen with clone GPE5; NK clones in-
cubatedwithanti-CD3 andTCRy/6-1
mAbs in parallel were not affected in
the lysis ofthese targets (not shown).
Despite the great potential diversity of the TCRy/S (predominantly due to the
junctional diversityofthe S chain) (1, 2, 30, 31), the number offunctionalgene com-
binations utilized by human peripheral y/S T cells appears quite limited (16-18).
The cytotoxicity pattern by the BB3/Ti-yA+ y/S clones was the same when using
clones obtained from two additional blood donors and comparing them with NK
and a/J3 clones derived from each ofthesedonors (not shown). Furthermore, asimilar
target spectrum (lysis ofDaudi but not the stimulator LCL) and the same produc-
tive Vy/S gene expression (assessed by mAb BB3 and TiyA) was independently de-
tected in all TCRy/S-1+, STCSI- clones derived from four different donors in Rot-
terdam. The results presentedhere strongly suggest that humanBB3/TiyA+ Tcells
recognize different determinants than non-MHC-restricted NKcells (3, 4) or IL-2-
activated MHC-restricted a/o T cells (31). The relationship of these target struc-
turesto known antigens fory/S T cells remains to be determined (12-14, 32). How-
ever, these target structures cannot be related to HLA class I since Daudi cells do
not express 02m-associated determinants. The target molecules are probably notFISCH ET AL.
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typicalHLA class II determinants since 25 allogeneicLCL includingthe stimulator
LCL (except forTK6), which express a range ofdiverse class II antigens, were resis-
tant to lysis by all our y/b clones (not shown). Furthermore, mAbs directed against
HLA-DR, -DP, or -DQdid not inhibit lysis ofDaudibythesey/b cells (not shown).
It is noteworthy that ally/b clones that had been derived with autologous LCL and
PBL stimulators, and thus were never exposed to allogeneic determinants in vitro,
still mediated the typical pattern of cytolysis. These results support the idea that
our y/b clones probably do not recognize polymorphic or nonpolymorphic MHC
molecules as suggested for othery/b cells (26, 28, 33-35). It is conceivable that our
y/b cells could recognize relatively nonpolymorphic determinants that are expressed
in sufficient quantities on only a minority of target cells. If the TCR-y/b is in fact
the receptor that reacts to such determinants, it is possible that such epitopes func-
tion as "superantigens" for BB3/TiyA+ cells. Indeed, the epitopes on some tumor
targets could be related to heat-shock proteins contained in mycobacterial prepara-
tions (12-14, 32, 36). It will be interesting to compare the function and specificity
ofour BB3/TiyA+ clones with BTCSI+ clones, other non-MHC-restricted cytolytic
y/b T cells (26-28), and clones derived from different tissues (30, 32). Although the
physiologic role and function ofy/b T cells remainselusive, ourdata clearly indicate
that the recognition ofsome target cells by our BB3/TiyA+ T cell clones is markedly
different from other non-MHC-restricted lymphoid cells.
Summary
Non-MHC-restricted killer cells are cytotoxic lymphocytes that can mediate cy-
tolysis ofmost tumortargetswithout apparent selectivityandrestriction bythe MHC,
particularly when activated with IL-2. These effector cells include predominantly
NK cells and T cells expressing the TCRy/& We found thatTCRy/b-1+, BTSC1-,
BB3+, TiyA+ T cell clones mediate a characteristic cytolytic pattern ofnon-MHC-
restricted cytolysis that is markedly different from NK clones and a/(3 T cell clones
derived from the peripheral blood ofthe same normal individuals. The character-
istic finding is that all BB3/TiyA+ y/b clones mediate strong cytolysis ofDaudi cells
buttheydo notlyseRajicells. In contrast, NKclones from the same donors mediate
strong cytolysis ofboth Daudi and Raji targets. Cytotoxicity by the 'Y/b clones on
certain target cells such as Daudi and Molt 4 can be specifically inhibitedby mAbs
reactive againstthe TCR-y/& Therefore, the TCR-y/bontheseclones either directly
recognizes target epitopes on some tumor targets or it is involved in the regulation
oftheir cytotoxic function. The expression ofTCR-y/b products reacting with the
BB3 and TiyA mAbs reflects the usage ofidentical TCRy/b V region genes that
appear tobe associated withthe characteristic pattern ofnon-MHC-restricted cyto-
toxicity displayed by this major subset of human peripheral blood y/b cells.
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